Review Article

You have free access to this content

Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases

  1. Eugenio Cersosimo1,*,
  2. Ralph A. DeFronzo2

Article first published online: 28 FEB 2006

DOI: 10.1002/dmrr.634

Issue

Diabetes/Metabolism Research and Reviews

Diabetes/Metabolism Research and Reviews

Volume 22, Issue 6, pages 423–436, November/December 2006

Additional Information

How to Cite

Cersosimo, E. and DeFronzo, R. A. (2006), Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab. Res. Rev., 22: 423–436. doi: 10.1002/dmrr.634

Author Information

  1. 1

    Associate Professor of Medicine, Division of Diabetes, Department of Medicine, University of Texas Health Science Center, San Antonio, Texas, USA

  2. 2

    Professor of Medicine and Chief, Division of Diabetes, Department of Medicine, University of Texas Health Science Center, San Antonio, Texas, USA

*Division of Diabetes, Department of Medicine, Mail Code 7886, 7703 Floyd Curl Drive, San Antonio, Texas 78229-3900, USA.

Publication History

  1. Issue published online: 20 OCT 2006
  2. Article first published online: 28 FEB 2006
  3. Manuscript Accepted: 19 JAN 2006
  4. Manuscript Revised: 17 DEC 2005
  5. Manuscript Received: 2 SEP 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (212K)

References

  • 1
    Centers for Disease Control and Prevention. Fast Statistics Report, September 11, 2003, National Center for Health Statistics, Dept. of Health, USA.
  • 2
    American Heart Association. Heart Disease and Stroke Statistics-2003 Update. American Heart Association: Dallas, TX: 2002.
  • 3
    Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. WHO Guidelines. JAMA 2002; 228: 2709–2716.
  • 4
    Quinones MJ, Hernandez-Pamplona M, Schelbert H, et al. Coronary vasomotor abnormalities in insulin-resistant individuals. Ann Intern Med 2004; 140: 700–708.
  • 5
    Lteif AA, Han K, Mather KJ. Obesity, insulin resistance and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation 2005; 112: 32–38.
  • 6
    Makimattila S, Yki-Jarvinen H. Endothelial dysfunction in human diabetes. Curr Diab Rep 2002; 2: 26–36.
  • 7
    The seventh report of the joint national committee on Prevention, Detection, Evaluation, and Treatment of high blood pressure: the JNC 7 Report. JAMA 2003; 289: 2560–2572.
  • 8
    Balletshofer BM, Rittig K, Enderle MD, et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101(15): 1780–1784.
  • 9
    Vita JA, Keaney JF Jr. Endothelial function: a barometer for cardiovascular risk? Circulation 2002; 106: 640–642.
  • 10
    Ferrannini E, De Fronzo RA. Insulin Action In Vivo: Glucose Metabolism, in International Textbook of Diabetes Mellitus, Edited by DeFronzoRA, FerranniniE, KeenH, Zimmet.P. John Wiley & Sons, Ltd. England: 2004; 277–301.
  • 11
    Reaven G. Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607.
  • 12
    Richardson DK, Kashyap S, Bajaj M, et al. Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increase the expression of extracellular matrix genes in human skeletal muscle. J Biol Chem 2005; 10290–10297.
  • 13
    DeFronzo RA, Tobin JD. Andres. Glucose clamp technique: a method for the quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214–E223.
  • 14
    Bonadonna R, Saccomani M, Del Prato S, et al. Role of tissue-specific blood flow and tissue recruitment in insulin-mediated glucose uptake of human skeletal muscle. Circulation 1998; 98: 234–241.
  • 15
    Bjorntorp P. Visceral Obesity: a “civilization syndrome”. Obes Res 1993; 1: 206–222.
  • 16
    Baron AD. Hemodynamic actions of insulin. Am J Physiol 1994; 267: E187–E202.
  • 17
    Liang C-S, Doherty JU, Faillace R, et al. Insulin infusion in conscious dogs. Effects on systemic and coronary hemodynamics, regional blood flows, and plasma catecholamines. J Clin Invest 1982; 69: 1321–1336.
  • 18
    Vincent MA, Clerk LH, Lindner JR, et al. Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes 2004; 53: 1418–1423.
  • 19
    Coggins M, Lindner J, Rattigan S, et al. Physiologic hyperinsulinemia enhances human skeletal muscle perfusion by capillary recruitment. Diabetes 2001; 50: 2682–2690.
  • 20
    Baron AD, Steinberg HO, Chaker H, et al. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness. J Clin Invest 1995; 96: 786–792.
  • 21
    Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin: direct measurement in vascular endothelial cells. J Clin Invest 1996; 98: 894–898.
  • 22
    Vincent MA, Barrett EJ, Lindner JR, et al. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab 2003; 285: E123–E129.
  • 23
    Shaul PW. Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol 2002; 64: 749–774.
  • 24
    Vane J, Anggard E, Botting R. Regulatory function of the vascular endothelium. N Engl J Med 1990; 323: 27–36.
  • 25
    Caballero E, Arora S, Saouaf R, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999; 48: 1856–1862.
  • 26
    Ludmer P, Selwyn A, Shook T, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 1046–1051.
  • 27
    Kuvin JT, Karas RH. Clinical utility of Endothelial function testing. Ready for primetime. Circulation 2003; 107: 3243–3247.
  • 28
    Sorensen K, Celermajer D, Spiegelhalter D, et al. Non-invasive measurement of human endothelial-dependent arterial responses: accuracy and reproducibility. Br Heart J 1995; 74: 247–253.
  • 29
    Martin CM, Beltran Del-Rio A, Albrecht R, et al. Local cholinergic mechanisms mediate nitric oxide-dependent flow-induced vaso-relaxation in vivo. Am J Physiol 1996; 39: H442–H446, (Heart Circ. Physiology).
  • 30
    Corretti M, Anderson T, Benjamin E, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. J Am Coll Cardiol 2000; 36: 2192–2197.
  • 31
    Eskurza I, Seals DR, DeSouza DA, et al. Pharmacological vs. flow-mediated assessments of peripheral vascular endothelial vasodilatory function in humans. Am J Cardiol 2001; 88: 1067–1069.
  • 32
    Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes; results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC) -Potsdam study. Diabetes 2003; 52: 812–817.
  • 33
    Bannan S, Mansfield MW, Grant PJ. Soluble vascular adhesion molecules-1 and E-selectin levels in relation to vascular risk factors and to E-selectin genotype in the first degree relatives of NIDDM patients and in NIDDM patients. Diabetologia 1998; 41: 460–466.
  • 34
    Pradham AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin-6 and the risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327–334.
  • 35
    Williams SB, Cusco JA, Roddy MA, et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin dependent diabetes mellitus. J Am Coll Cardiol 1996; 27: 567–574.
  • 36
    Steinberg HO, Chaker H, Leaming R, et al. Obesity/insulin resistance is associated with endothelial dysfunction. J Clin Invest 1996; 97: 2601–2610.
  • 37
    Patterson GC, Whelan RF. Reactive hyperemia in the human forearm. Clin Sci 1955; 44: 197–211.
  • 38
    Steinberg HO, Bretchel G, Johnson A, et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. J Clin Invest 1994; 94: 1172–1179.
  • 39
    Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk for atherosclerosis. Lancet 1992; 340: 1111–1115.
  • 40
    Widlansky ME, Gokce N, Kearney JF, et al. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42: 1149–1160.
  • 41
    Engelke KA, Halliwill JR, Protcor DN, et al. Contribution of nitric oxide and prostaglandins to reactive hyperemia in the human forearm. J Appl Physiol 1996; 81(4): 1807–1814.
  • 42
    Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995; 91: 1314–1319.
  • 43
    Bjornberg J, Albert U, Mellander S. Resistance responses in proximal arterial vessels, arterioles and veins during reactive hyperemia in skeletal muscle and their underlying mechanisms. Acta Physiol Scand 1990; 139: 535–550.
    Direct Link:
  • 44
    Morris SJ, Shore AC, Tooke JE. Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with NIDDM. Diabetologia 1995; 38: 1337–1344.
  • 45
    DeFronzo RA. The triumvirate: beta cell, muscle and liver, a collusion responsible for NIDDM. Diabetes 1988; 37: 667–687.
  • 46
    Wiernsperger N. Vascular defects in the aetiology of peripheral insulin resistance in diabetes. A critical review of hypothesis and facts. Diabetes Metab Rev 1994; 10(3): 287–307.
    Direct Link:
  • 47
    Ader M, Bergman RN. Importance of transcapillary insulin transport to dynamics of insulin action after intravenous glucose. Am J Physiol 1994; 266(29): E17–E25.
  • 48
    Laakso M, Edelman SV, Bretchel G, et al. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 1990; 85: 1844–1852.
  • 49
    Olefsky J, Farquhar JW, Reaven G. Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects. Diabetes 1973; 22: 507–513.
  • 50
    Sjöstrand M, Gudbjörnsdottir S, Holmäng A, et al. Delayed transcapillary transport of insulin to muscle interstitial fluid in obese subjects. Diabetes 2002; 51: 2742–2748.
  • 51
    DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 1997; 5: 177–269.
  • 52
    Ebeling P, Bourey R, Koranyi L, et al. Mechanism of enhanced insulin sensitivity in athletes: increased blood flow, muscle glucose transport protein (GLUT-4) concentration and glycogen synthase activity. J Clin Invest 1993; 92: 1623–1631.
  • 53
    Clark MG, Wallis MG, Barrett EJ, et al. Blood flow and muscle metabolism: a focus on insulin. Am J Physiol 2002; 284: E241–E258.
  • 54
    Steinberg HO, Paradisi G, Hook G, et al. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 2000; 49: 1231–1238.
  • 55
    Baron AD, Bretchel G. Insulin differentially regulates systemic and skeletal muscle vascular resistance. Influence of insulin sensitivity. Am J Physiol 1993; 265: E61–E67.
  • 56
    Pisters P, Restifo NP, Cersosimo E, et al. The effects of euglycemic hyperinsulinemia and amino acid infusion on regional and whole body glucose disposal in man. Metabolism 1991; 40(1): 59–65.
  • 57
    Dela F, Larsen JJ, Mikines KJ, et al. Normal effect of insulin to stimulate leg blood flow in NIDDM. Diabetes 1995; 44: 221–226.
  • 58
    Baron AD, Steinberg HO, Bretchel G, et al. Skeletal muscle blood flow independently modulates insulin-mediated glucose uptake. Am J Physiol 1994; 266: E248–E253.
  • 59
    Yki-Jarvinen H, Utriainen T. Insulin-induced vasodilation: physiology or pharmacology? Diabetologia 1998; 41: 369–379.
  • 60
    Natali A, Bonadonna R, Santoro D, et al. Insulin resistance and vasodilation in essential hypertension. Studies with adenosine. J Clin Invest 1994; 94: 1570–1576.
  • 61
    Nuutila P, Raitakari M, Laine H, et al. Role of blood flow in regulating insulin insulin-stimulated glucose uptake in humans. Studies using bradykinin, [15O] water, and [18F] fluor-deoxy-glucose and positron emission tomography. J Clin Invest 1996; 97: 1741–1747.
  • 62
    Jamerson JK, Nesbitt SD, Amerena JV, et al. Angiotensin mediates forearm glucose uptake by hemodynamic rather than direct effects. Hypertension 1996; 27: 854–858.
  • 63
    Guyton AC. Physics of Blood, Blood Flow, and Pressure: Hemodynamics. In Guyton's Textbook of Medical Physiology. W.B Saunders Co, USA: 1984; 213.
  • 64
    Andersen P, Henriksson J. Capillary supply of the quadriceps femoris muscle of man: adaptive response to exercise. J Physiol 1977; 270: 677–690.
  • 65
    Vincent MA, Dawson D, Clark ADH, et al. Skeletal muscle microvascular recruitment by physiological hyperinsulinemia precedes increases in total blood flow. Diabetes 2002; 51: 42–48.
  • 66
    Cersosimo E. Relationship Between Hemodynamic and Metabolic Insulin Action, Nutrition Week Symposium, A.S.P.E.N. Meeting, San Antonio, TX, 2002; January 22.
  • 67
    Scherrer U, Randin D, Vollenweider P, et al. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994; 94: 2511–2515.
  • 68
    Zeng G, Nystrom FH, Ravichandran LV, et al. Roles of insulin receptor, PI3-kinase, and Akt I insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000; 101: 1539–1545.
  • 69
    Kuboki K, Jiang ZY, Takahara N, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo. Circulation 2000; 101: 676–681.
  • 70
    Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345: 588–595.
  • 71
    Davis M, Hill MA. Signaling mechanisms underlying the vascular myogenic response. Physiol Rev 1999; 79(2): 387–423.
  • 72
    Zeng G, Quon MJ. Insulin stimulated production of nitric oxide is inhibited by Wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996; 98: 894–898.
  • 73
    Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia 2002; 45: 623–634.
  • 74
    Lundman P, Eriksson M, Schenck-Gustafson K, et al. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary artery disease. Circulation 1997; 96: 3266–3268.
  • 75
    Arcaro G, Cretti A, Balzano S. Insulin causes endothelial dysfunction in humans. Circulation 2002; 105: 576–588.
  • 76
    Tripathy D, Mohanty P, Dhindsa S, et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003; 52: 2882–2887.
  • 77
    Aulak KS, Koeck T, Crabb JW, et al. Dynamics of protein nitration in cells and mitochondria. Am J Physiol 2004; 286: H30–H38, (Heart Circ. Physiol).
  • 78
    Natali A, Baldeweg S, Toschi E. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004; 27(6): 1349–1357.
  • 79
    Satoh N, Ogawa Y, Usui T. Anti-atherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its anti-diabetic effect. Diabetes Care 2003; 26: 2493–2499.
  • 80
    DeFillipis E, Miyazaki Y, Cersosimo E, et al. Exercise training, vascular endothelial function and insulin sensitivity in patients with type 2 diabetes (Abstract). Diabetes 2003; 51(Suppl. 1): A238.
  • 81
    Zhang L, Vincent MA, Richards SM, et al. Insulin sensitivity of muscle capillary recruitment in vivo. Diabetes 2004; 53: 447–453.
  • 82
    Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term followup of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 1899–1906.
  • 83
    Wajcberg E, Fernandez M, Cersosimo E, et al. Relationship between insulin sensitivity and endothelial function in type 2 diabetic individuals (Abstract). Diabetes 2004; 53(Suppl. 1): A177.
  • 84
    Berenson GS, Srinivasan RS, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med 1998; 338: 1650–1656.
  • 85
    King GL, Hachiya Hl, Kwok CF, et al. Characterization of the effects of insulin, IGF, and hyperglycemia on the metabolism and function of vascular endothelial cells. In Endothelial Cell Function in Diabetic Microangiopathy, MolinattiGM, BarRS, BelfioreF, PortaM (eds). Karger: Basel, 1990; 86–89.
  • 86
    Stevens MJ, Edmonds ME, Foster AVM, et al. Paradoxical blood flow responses in the diabetic neuropathic foot: an assessment of the contribution of vascular denervation and microangiopathy. Diabet Med 1992; 9: 49–54.
    Direct Link:
  • 87
    Schachinger V, Britten M, Zeiher A. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary artery disease. Circulation 2000; 101: 1899–1906.
  • 88
    Halcox J, Schenke W, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 653–658.
  • 89
    Hollenberg S, Klein L, Parrillo J, et al. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation 2001; 104: 3091–3096.
  • 90
    Anderson T, Uehata A, Gerhard M, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235–1241.
  • 91
    Gaeta G, De Michele M, Guomo S, et al. Arterial abnormalities in the offspring of patients with premature myocardial infarction. N Engl J Med 2000; 343: 840–846.
  • 92
    Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 2003; 107: 499–511.
  • 93
    Festa A, D'Agostino R Jr., Tracy RP, et al. Elevated levels of acute-phase protein and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 2002; 51: 1131–1137.
  • 94
    Huang ES, Meigs JB, Singer DE. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 2001; 111: 633–642.
  • 95
    Gaeda P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–393.
  • 96
    Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002; 360: 2–3.
  • 97
    Malberg K, Norhammar A, Wedel H, et al. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction. Long-term results from the diabetes and insulin-glucose in acute myocardial infarction (DIGAMI) study. Circulation 1999; 99: 2626–2632.
  • 98
    Van Der Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345: 1359–1367.
  • 99
    Pitrosch F, Passauer J, Fischer S, et al. In type 2 diabetes, Rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004; 27(2): 484–490.
  • 100
    Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452–3456.
  • 101
    Bajaj M, Suraamornkul S, Cersosimo E, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89(1): 200–206.
  • 102
    Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the heart outcomes prevention evaluation study investigators. N Engl J Med 2000; 342: 145–153.
  • 103
    Prasad A, Tupas-Habib T, Shenke WH, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101: 2349–2354.
  • 104
    Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001; 103: 799–805.
  • 105
    Kiowski W, et al. Calcium-channel blockers reverse vasoconstriction induced buy endothelin-1. J Hypertens 1994; 24(suppl 1): S21–S26.
  • 106
    Leung WH, Lau CP, Wong CK, et al. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993; 341: 1496–1500.
  • 107
    Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481–487.
  • 108
    Rask-Madsen C, Ihlemann N, Krarup T, et al. Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes 2001; 50: 2611–2618.
  • 109
    Mather KJ, Verma S, Anderson TJ, et al. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001; 37: 1344–1350.
  • 110
    Barnes PJ, Karin M. Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066–1071.
  • 111
    Hambrecht R, Wolf A, Gielen S, et al. Effect of physical exercise on coronary endothelial function in coronary artery disease. N Engl J Med 2000; 342: 452–460.
  • 112
    Clarkson P, Montgomery HE, Mullen MJ, et al. Exercise training enhances endothelial function in young men. J Am Coll Cardiol 1999; 33: 1379–1385.
  • 113
    Celermajer DS, Sorensen KE, Georgakopolous D, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelial-dependent dilation in healthy young adults. Circulation 1993; 88: 2149–2155.
  • 114
    Harrison DG, Armstrong ML, Frieman PC, et al. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 1987; 80: 1808–1811.
  • 115
    Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol lowering and antioxidant therapy of endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332: 488–493.
  • 116
    Agewall S, Wright S, Doughty RN, et al. Does a glass of red wine improve endothelial function? Eur Heart J 2000; 21: 74–78.
  • 117
    Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate anti-diabetic metabolic effects. Nature 2003; 423: 762–769.
  • 118
    Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med 1999; 340: 115–126.
  • 119
    Ferri C, Pittoni V, Piccoli A, et al. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J Clin Endocrinol Metab 1995; 80: 829–835.
  • 120
    Neunteufel T, Katzenschlanger R, Hassan A, et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997; 129: 111–118.
  • 121
    Schling P, Loffler G. Cross talk between adipose tissue cells: impact on pathophysiology. News Physiol Sci. 2002; 17: 99–104.
View Full Article (HTML) Get PDF (212K)